Fifth Third Bancorp Has $278,000 Stake in Alexion Pharmaceuticals, Inc. (ALXN)

Share on StockTwits

Fifth Third Bancorp reduced its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 84.7% in the third quarter, HoldingsChannel.com reports. The fund owned 1,998 shares of the biopharmaceutical company’s stock after selling 11,096 shares during the quarter. Fifth Third Bancorp’s holdings in Alexion Pharmaceuticals were worth $278,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Bain Capital Public Equity Management LLC raised its stake in Alexion Pharmaceuticals by 23.2% in the second quarter. Bain Capital Public Equity Management LLC now owns 70,753 shares of the biopharmaceutical company’s stock valued at $8,784,000 after purchasing an additional 13,318 shares in the last quarter. Honeywell International Inc. raised its stake in Alexion Pharmaceuticals by 42.3% in the third quarter. Honeywell International Inc. now owns 127,600 shares of the biopharmaceutical company’s stock valued at $17,738,000 after purchasing an additional 37,900 shares in the last quarter. Brown Advisory Inc. raised its stake in Alexion Pharmaceuticals by 297.9% in the second quarter. Brown Advisory Inc. now owns 20,261 shares of the biopharmaceutical company’s stock valued at $2,516,000 after purchasing an additional 15,169 shares in the last quarter. DNB Asset Management AS raised its stake in Alexion Pharmaceuticals by 3.7% in the third quarter. DNB Asset Management AS now owns 27,175 shares of the biopharmaceutical company’s stock valued at $3,778,000 after purchasing an additional 967 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its stake in Alexion Pharmaceuticals by 146.8% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 36,237 shares of the biopharmaceutical company’s stock valued at $5,037,000 after purchasing an additional 21,555 shares in the last quarter. Institutional investors own 93.31% of the company’s stock.

ALXN stock opened at $105.99 on Wednesday. The company has a market cap of $24.44 billion, a price-to-earnings ratio of 20.54, a price-to-earnings-growth ratio of 0.94 and a beta of 1.02. Alexion Pharmaceuticals, Inc. has a one year low of $102.10 and a one year high of $140.77. The company has a current ratio of 3.16, a quick ratio of 2.74 and a debt-to-equity ratio of 0.32.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter last year, the business earned $1.44 earnings per share. The business’s revenue was up 19.5% on a year-over-year basis. On average, analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.82 EPS for the current year.

In other news, EVP Indrani Lall Franchini sold 2,605 shares of the firm’s stock in a transaction that occurred on Wednesday, November 28th. The shares were sold at an average price of $118.13, for a total value of $307,728.65. Following the transaction, the executive vice president now owns 29,304 shares in the company, valued at $3,461,681.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.35% of the stock is currently owned by company insiders.

A number of brokerages recently weighed in on ALXN. BidaskClub raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 29th. Barclays raised their target price on shares of Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a research note on Friday, September 28th. ValuEngine downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 5th. Finally, Credit Suisse Group set a $156.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 25th. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $161.50.

COPYRIGHT VIOLATION WARNING: “Fifth Third Bancorp Has $278,000 Stake in Alexion Pharmaceuticals, Inc. (ALXN)” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://weekherald.com/2018/12/19/fifth-third-bancorp-has-278000-stake-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Further Reading: Google Finance Portfolio Workaround

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply